Home Tags Amal Therapeutics

Tag: Amal Therapeutics

Boehringer Ingelheim acquires Swiss biotech Amal Therapeutics

Amal’s lead vaccine ATP128 is currently being developed for stage IV colorectal cancer and is slated to begin its first-in-human trials later this month.